MSI-H Cancer: Clinical Trials

8 trials for MSI-H Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 active not recruiting, 1 completed. 6 Phase 2, 5 Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 26Active not recruiting 3, Recruiting 3
Phase 15Active not recruiting 3, Recruiting 2
Not applicable1Completed 1

Follow MSI-H Cancer: new trials by email Literature Review of MSI-H Cancer trials Research Report on MSI-H Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
Iparomlimab and Tuvonralimab, First line chemotherapy plus PD-1/PD-L1 antibody - Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Phase 2RecruitingPeking University1062025-12-152026-08-05
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA-341, Irinotecan, Immunotherapy - Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1RecruitingMOMA Therapeutics1322025-07-162026-07-23
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NDI-219216 - Advanced Solid Tumors Cancer, MSI-H Cancer
Phase 1 / Phase 2RecruitingNimbus Wadjet, Inc.1342025-03-312026-05-06
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Tiragolumab and atezolizumab - Head and Neck Neoplasms, MSI-H Cancer
Phase 2RecruitingUniversity Medical Center Groningen972023-10-182025-03-30
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside
Arterial Doppler for Flow Mediated Reserve measurement - Renal Cell Carcinoma, Bladder Cancer
Not applicableCompletedInstitut Mutualiste Montsouris392023-06-072026-04-08
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Decoy20, Tislelizumab - Solid Tumor, Adult, HCC - Hepatocellular Carcinoma
Phase 1 / Phase 2Active not recruitingIndaptus Therapeutics, Inc1202023-02-282026-01-13
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23ME-00610 - Solid Tumor, Clear Cell Renal Cell Carcinoma
Phase 1 / Phase 2Active not recruiting23andMe, Inc.1412021-12-292024-11-15
A Beta-only IL-2 ImmunoTherapY Study
MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor
Phase 1 / Phase 2Active not recruitingMedicenna Therapeutics, Inc.1602021-08-272026-10-30

Narrower conditions

Carcinoma, Renal Cell (3)  ·  Colorectal Neoplasms (3)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Endometrial Neoplasms (2)  ·  Fallopian Tube Neoplasms (2)  ·  Melanoma (2)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)  ·  Stomach Neoplasms (2)  ·  Urinary Bladder Neoplasms (2)  ·  Atherosclerosis (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Non-Small-Cell Lung (1)

Broader conditions

Neoplasms by Site (6)  ·  Neoplasms by Histologic Type (5)  ·  Adenocarcinoma (4)  ·  Carcinoma (4)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Neoplasms (4)  ·  Neoplasms, Glandular and Epithelial (4)  ·  Urogenital Diseases (4)  ·  Urogenital Neoplasms (4)  ·  Colonic Diseases (3)  ·  Digestive System Diseases (3)  ·  Digestive System Neoplasms (3)  ·  Gastrointestinal Diseases (3)  ·  Gastrointestinal Neoplasms (3)

Interventions

Blood Specimen Collection (1)  ·  Immunotherapy (1)  ·  Interleukin-2 (1)  ·  Irinotecan (1)  ·  Tiragolumab (1)  ·  atezolizumab (1)  ·  pembrolizumab (1)  ·  tislelizumab (1)

Sponsors

23andMe, Inc. (1)  ·  Indaptus Therapeutics, Inc (1)  ·  Institut Mutualiste Montsouris (1)  ·  MOMA Therapeutics (1)  ·  Medicenna Therapeutics, Inc. (1)  ·  Nimbus Wadjet, Inc. (1)  ·  Peking University (1)  ·  University Medical Center Groningen (1)

Countries

United States (5)  ·  Australia (3)  ·  Canada (3)  ·  France (2)  ·  Ireland (2)  ·  Portugal (2)  ·  Spain (2)  ·  China (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Anita Scheuber, MD, PhD (1)  ·  Arash Yavari, MBBS (1)  ·  Derk JA de Groot, MD PhD (1)  ·  Nina Merchant (1)

Results publications

PMID 39651931

NIH funding

2023 (1)